NRX Pharmaceuticals (NRXP) Retained Earnings (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Retained Earnings data on file, last reported at $294.5 million in Q1 2026.

• On a quarterly basis, Retained Earnings rose 13.87% year-over-year to $294.5 million in Q1 2026; TTM through Mar 2026 was $294.5 million, a 13.87% increase from a year earlier, with the FY2025 full-year figure at -$306.9 million, down 10.29% from the prior year.
• Retained Earnings for Q1 2026 stood at $294.5 million, up from -$306.9 million in the prior quarter.
• Over the last five years, Retained Earnings for NRXP reached as high as $294.5 million in Q1 2026 and fell as low as -$307.3 million in Q3 2025.
• Historically, Retained Earnings has averaged -$56.2 million across 5 years, with a median of -$22000.0 in 2023.
• Across the five-year window, Retained Earnings plunged 1223513.64% in 2024 and jumped 8620333.33% in 2025, its largest moves.
• Year by year, Retained Earnings stood at $230.3 million in 2022, then plunged by 209.9% to -$253.1 million in 2023, then declined by 9.93% to -$278.3 million in 2024, then slipped by 10.29% to -$306.9 million in 2025, then jumped by 195.95% to $294.5 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $294.5 million in Q1 2026, -$306.9 million in Q4 2025, and -$307.3 million in Q3 2025.